CDK12 and ovarian serous adenocarcinoma: defined a unique defect characterized by numerous FTDs and intact HR in the 4% of serous ovarian cancers lacking functional CDK12. 20The same held true in our mCRPC exome sequencing study, as CDK12-mutant tumors constituted a unique mCRPC subtype, genetically distinct from those with other primary genetic drivers, including HRD.18